A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine

Overview of attention for article published in Science Translational Medicine, May 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

news: 3 news outlets
blogs: 1 blog
policy: 1 policy source

twitter: 9 X users
bluesky: 3 Bluesky users

Readers on

mendeley: 9 Mendeley

So far, Altmetric has seen 9 X posts from 9 X users, with an upper bound of 1,236,701 followers.

Plataforma ChAdOx1 sendo utilizada pra expressar antígenos de N. meningitidis. A ver (pincipalmente se será equivalente a tradicional Bexsero da GSK) https://t.co/8EVBy5Nebs

RT @medical_xpress: #A gene-based #Vaccine targeting group B meningococcus has demonstrated safety and strong immune responses in adults, s…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 5 additional X posts.